Coeptis Therapeutics, Inc.
NASDAQ:COEPBiotechnology
+$0.73 today
- Market cap
- $57.63M
- Beta
- -0.43
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$1.97
Volume 0.18M
Average 0.05M
COEP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Coeptis Therapeutics, Inc.NASDAQ: COEP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $235.53K rose 171.8% year over year, ahead of the -13.1% change in trailing-twelve-month research & development. Sequentially, it fell 24.7% from the prior quarter. Over 3 fiscal years it compounded at +294.0% a year.
Context
- Research & development amounted to 93.7% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +171.8% holds above the trailing-twelve-month pace of -13.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.28M USD
- Year-over-year change
- -45.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.28M | -45.2% |
| FY2024 | 2024-12-31 | 2.33M | -65.0% |
| FY2023 | 2023-12-31 | 6.67M | +31825.3% |
| FY2022 | 2022-12-31 | 20.89K | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How COEP compares with its peers on the latest reported figures
- COEP's LTM Mar 2026 research & development of $1.43M is the lowest of the 9 companies compared; the peer median is $28.64M.
- Its year-over-year change of -13.1% is the 5th highest of 9, against a peer median of -15.4%.
- Research & development amounts to 100.9% of revenue for COEP, versus a peer median of 148.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $16.37B | +432309.4% | +1606.6% | — |
| LTM Mar 2026 | $124.78M | -12.3% | -5.5% | 82.6% | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $36.03M | +4.0% | -0.7% | 110.1% | |
| LTM Mar 2026 | $21.25M | -43.8% | +8527.1% | 6378.2% | |
| LTM Mar 2026 | $9.91M | -70.5% | -30.1% | — | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| LTM Mar 2026 | $2.57M | +40.4% | +43.0% | — | |
| LTM Mar 2026 | $1.43M | -13.1% | +294.0% | 100.9% | |
| Peer median (excluding COEP) | $28.64M | -15.4% | -0.6% | 148.4% | |
Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75K | 0 | 0 | 0 | 1.36M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 180.63K |
| Gross Profit | 75K | 0 | 0 | 0 | 1.18M |
| Gross Margin | 100.0% | — | — | — | 86.7% |
| Research & Development | 0 | 20.89K | 6.67M | 2.33M | 1.28M |
| Selling, General & Admin | 14.12M | 34.18M | 13.82M | 6.72M | 11.95M |
| Operating Expenses | 14.12M | 34.2M | 21.49M | 10.05M | 14.23M |
| Depreciation & Amortization | 447.41K | 1M | 1.04M | 1.04M | 1.22M |
| EBITDA | (12.81M) | (36.35M) | (20.12M) | (9.38M) | (10.41M) |
| EBITDA Margin | -17086.3% | — | — | — | -763.9% |
| Operating Income | (14.05M) | (34.2M) | (21.49M) | (10.05M) | (13.04M) |
| Operating Margin | -18727.9% | — | — | — | -956.9% |
| Interest Income | 0 | 0 | 0 | 0 | 116.5K |
| Interest Expense | 187.13K | 218.41K | 107.69K | 396.12K | 642.38K |
| Other Income / Expenses | 596.65K | (3.38M) | 224.59K | (822.92K) | 766.31K |
| Income Before Tax | (13.45M) | (37.57M) | (21.27M) | (10.88M) | (12.28M) |
| Pre-Tax Margin | -17932.4% | — | — | — | -900.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (13.45M) | (37.57M) | (21.27M) | (10.68M) | (11.92M) |
| Net Margin | -17932.4% | — | — | — | -874.3% |
| EPS (Basic) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| EPS (Diluted) | (13.16) | (2.87) | (0.83) | (5.65) | (2.81) |
| Weighted Avg Shares | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
| Weighted Avg Shares (Diluted) | 1.02M | 14.3M | 25.69M | 1.93M | 4.23M |
Coeptis Therapeutics, Inc.
NASDAQ:COEP
Intrinsic Alpha fair value
Locked
Current Price
$14.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.